奥希替尼期间寡进展病灶放疗：EGFR 突变肺癌回顾性研究
类型: 回顾性研究 / 放疗 发表日期: 2025-05-15 入库日期: 2026-05-21 来源: PubMed / JCO Precision Oncology 标签: EGFR L858R, 奥希替尼, 寡进展, 放疗, 局部控制
Citation
Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With EGFR-Mutant Lung Cancer Treated With Osimertinib. JCO Precision Oncology. 2025. PMID: 40373257. DOI: 10.1200/PO-25-00047
Why it matters for mom
Her sternum lesion and bone-dominant pattern make radiation oncology consultation important if progression is anatomically limited or symptomatic. This paper directly studies radiation to oligoprogressive sites in patients on osimertinib.
Practical takeaways
- Radiation for oligoprogression is a way to delay systemic therapy change in selected patients.
- Benefit depends on number of progressing lesions, pace of disease, and safety of the radiation field.
- Bone lesions also raise skeletal-related-event questions, not only tumor response questions.
Questions for doctors
- Would the sternum lesion qualify as an oligoprogressive target?
- Is radiation needed for pain prevention, local control, or fracture/structural risk?
- Should biopsy be done before radiation if transformation/resistance mechanism is a concern?